Kidney Cancer

Good morning everyone this is the link of the Italian Kidney Cancer group ❤️ Athos MANDRELLI facebook.com/share/g/5Cg4XC…

💡 LITESPARK-011 Trial: Robert Motzer, MD (@motzermd), and colleagues find #belzutifan plus #lenvatinib may be a new treatment option for patients with advanced #ccRCC whose disease has progressed after anti-PD-(L)1 therapy in the first-line, second-line, or adjuvant therapy: buff.ly/doGQi4M

This exploratory plot by @BethN01 suggests prior immune therapy in RCC may augment outcomes with subsequent VEGF TKIs (orange vs blue). There are a number of potentially confounding factors, but IO has long term effects (partly why rechallange failed) and could augment the activity of subsequent therapy #JSMO26. @DrChoueiri @montypal @OncoAlert @neerajaiims

Treatment Algorithm: #KidneyCancer discussion w/ @katy_beckermann ✅ Adj Rx ✅ Rx options for metastatic disease ✅ Sequencing ✅ #GU26 @ASCO updates Full 🗣️: ⭐️ OncBrothers & @OncUpdates Website ⭐️ “Oncology Brothers” podcast #OncTwitter #gusm #MedTwitter #MedX

Hello everyone, We are hosting our first kidney cancer symposium in Connecticut for individuals with kidney cancer and their caregivers. Register here: registration.curetoday.com/eps_kidney_apr… Please re-tweet and help spread the word! @YaleCancer @KidneyCancer @kidneycan @kcCURE @OncBrothers @OncoAlert @DrChoueiri @Uromigos @KidneyCAN4KCRS @OncLive @kaydaustin @smart_patients

Outstanding Plenary by Srinivas Viswanathan at @DanaFarber who spoke about molecular insights into a rare kidney cancer (translocation RCC) and other lessons learned at #LegorretaCancerCenter 2026 TRDG Retreat at @BrownUniversity. @SenduraiMani

In metastatic renal cell carcinoma, pancreatic spread is associated with improved survival. doi.org/10.1172/jci.in… Here, James Brugarolas @JBrugarolas & team @KCPUTSW @UTSWMedCenter determine that pancreatic #metastases arise predominantly from indolent clones within primary #RCC and exhibit distinct molecular and histological features, clinical behavior, and treatment responsiveness. The figure shows pancreatic metastasis sample with high angiogenesis, indicated by deep learning vascular mask (red).

Honored to be part of this @sitcancer guideline on IO for #KidneyCancer This work offers evidence- & consensus-based recommendations for adjuvant & metastatic RCC, special populations, response monitoring, & patient education/QOL @DrRanaMcKay @montypal jitc.bmj.com/content/14/3/e…

NICE 2026 guideline for the diagnosis and management of #kidneycancer : 👉doi.org/10.1016/S1470-… @OncoAlert #cancer #oncology @DrYukselUrun @urotoday @AUC3_Official

Savolitinib + durvalumab shows promising survival in MET-driven papillary renal cancer (CALYPSO study). ORR 53%, OS up to 27 months. 👉Supports ongoing phase III SAMETA trial. @DrChoueiri @DrYukselUrun @OncoAlert #cancer #oncology #kidneycancer @JCO_ASCO doi.org/10.1200/JCO-25…

Our Coverage from #GU26 Continues We are proud to have Dr. @Clara__Steiner 🇩🇪@DanaFarber 🇺🇸share with you her poster Presented in San Francisco Pilot phase I trial of an implantable microdevice for in vivo evaluation of drug response in renal cell carcinoma. This pilot phase I study evaluated implantable microdevices (IMDs) delivering microdoses of multiple drugs directly into renal cell carcinoma tumors. In 10 patients, CT-guided IMD placement before surgery proved safe and feasible, with successful tissue analysis in most cases. The approach revealed spatial, drug-specific effects on apoptosis, proliferation, and immune composition, demonstrating the potential of IMDs to guide personalized therapy selection while avoiding systemic toxicity. #KidneyCancer @DrChoueiri @MattMossanen @MichelleDunno17 @bergsa83 @MikeSerzanMD @BradMcG04 @srviswanathan @stusilverman @VincentWenxinXu @motzermd @DrIacovelli @DrYukselUrun @elena_verzoni @tompowles1 @montypal @crisbergerot @DrDanielHeng @apolo_andrea @PGrivasMDPhD @TiansterZhang @neerajaiims @amerseburger @drenriquegrande @BraunMDPhD @cdanicas @brian_rini @AUC3_Official @nataliagandur @MarcMachaalani @Mustafajsalehmd @NazliDizman @DrYukselUrun @yekeduz_emre @WeiweiBian @ReneeSaliby @eddy_saad @marc_eid @pablombarrios @WDKhatoun @Jad_El_Masri @lilli_ash @RashadNawfal @RazaneHChehade @elioibrahim8 @NafehGaelle @shaye_carver @zeyun_lu @SylvanBacaLab

Pleased to share our study published in @CCR_AACR 👉 doi.org/10.1158/1078-0… 📍NF2 loss (merlin deficiency) in RCC delineates a distinctly aggressive biological phenotype: ⏫ heightened proliferative capacity, profound immune dysregulation, and recurrent alterations in cell cycle and DNA damage–response pathways. ⏬ limited efficacy of immunotherapy further underscores the pressing need for biomarker-driven, molecularly tailored therapeutic strategies. #Oncology #cancer #kidneycancer @DrChoueiri @MikeSerzanMD @WeiweiBian @OncoAlert @DanaFarberNews @DanaFarber_GU @AnkaraUni

The #OncoAlertColloquium 2026 GU Malignancies🚨 #EAU26 Presentation by Dr. Brian Rini: Year in Review in Renal Cell Carcinoma #KidneyCancer REGISTER HERE TO WATCH: buff.ly/pDEvKKw Brian Rini’s 2025 year-in-review highlights real progress—and ongoing challenges—in kidney cancer Adjuvant pembrolizumab remains the global standard, with durable DFS & OS benefits, while other adjuvant IO trials were negative. New RAMPART data suggest durvalumab + tremelimumab may benefit only the highest-risk patients, underscoring the need for better risk stratification 📊. KIM-1 has emerged as a promising blood-based prognostic biomarker (prospective validation needed ). In refractory disease, combination strategies show greater activity but higher toxicity, with survival data still maturing. In non–clear cell RCC, IO doublets and belzutifan-based combinations are reshaping standards of care 🚀 GU Oncology Colloquium Faculty @brian_rini 🇺🇸 @tompowles1 🇬🇧 @declangmurphy 🇦🇺 @KidneyCancer🇺🇸 @salvolarosa @silkegillessen 🇨🇭 @RenuEapen🇦🇺 @nataliagandur 🇦🇷 @seanmcbride 🇺🇸 @DrJaVallejo 🇪🇸 #OncoAlertAF @acampsmalea @BRicciutiMD @HHorinouchi @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @DrRishabhOnco @Onco_Cifu88 @PaulJiL Our Partners @ESGO_society @ESSOnews @CancerCareMASCC @SIOGorg Our Collaborators @APCCC_Lugano @gu_onc @Uromigos @montypal @crisbergerot @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen @cdanicas @AOmlin

Marzo es el Kidney Cancer Awareness Month 🧡 Cada año se diagnostican más de 430.000 nuevos casos de cáncer renal en el mundo, situándolo entre los 10 tumores más frecuentes a nivel global. La investigación clínica y las terapias dirigidas están mejorando de forma significativa la supervivencia en enfermedad avanzada. #KidneyCancerAwarenessMonth #RenalCancer #RCC #GUOncology #Oncology @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1

🧬 Fascinating translational work from @BraunMDPhD lab by Dr. Rout at #AACRkidney2026 Single-cell transcriptomics of tumor-infiltrating CD8+ T cells in ICI-resistant RCC 🔬 Key findings: ➡️ Insufficient T cell infiltration is a core feature of ICI resistance in RCC ➡️ TGFB1 emerges as a potential driver of the exhausted resident memory T cell phenotype ➡️ This Tex-rm phenotype correlates with resistance to immune checkpoint inhibition Why this matters: 💡 TGFB1 has long been implicated in immune exclusion, but pinpointing its role in shaping a specific exhausted T cell state in RCC gives us a more precise therapeutic target If TGFB1 is locking CD8+ T cells into an exhausted resident memory fate or excluding CD8 T cells from TME, anti-TGFb strategies combined with ICI may deserve a closer look in biomarker-selected RCC patients 🎯 Single-cell resolution is revealing what bulk analyses miss. This is the kind of mechanistic work that drives the next generation of rational combinations. 👏 #KidneyCancer #RCC #Immunotherapy #ICIResistance #TGFbeta #SingleCell #Tcells #GUOnc #AACRkidney2026

Time of Day administration of ICI better in the morning in this retrospective study in @KidneyCancer. Makes prospective trials on this topic important. Congrats on this oral presentation at #EAU26 @Uroweb @Uromigos @OncoAlert

Latest @ASCOPost Daily News piece highlighting the value of more precise, histology-driven approach to therapy selection in rare #kidneycancer subtypes: dailynews.ascopubs.org/do/bevacizumab…

🔥 RENAL CELL CARCINOMA – The Big Signals from #AGU26 @ASCO Kidney cancer delivered. Biology is driving the next standards. 🟡 1️⃣ LITESPARK-011 Belzutifan + lenvatinib > cabozantinib post IO • mPFS 14.6 vs 10.0 mo • HR 0.74 First phase III HIF-2α + VEGFR-TKI win. 🟡 2️⃣ LITESPARK-022 (Adjuvant) Pembro + belzutifan improved DFS • HR 0.72 • 28% recurrence risk reduction Clear applause moment in the room. 🟡 3️⃣ RAMPART (PROs) Durva + treme vs monitoring • Early QoL cost Adjuvant IO = benefit ⚖️ burden conversation. 🟡 4️⃣ The Meta-Shift • MRD concepts entering GU • Molecular endpoints rising • Biology-driven combinations consolidating 💬 Kidney cancer is no longer just VEGF vs IO. It’s HIF biology. It’s intensification. It’s personalization. @DrChoueiri @montypal @motzermd @brian_rini @tompowles1 @apolo_andrea @PGrivasMDPhD @urotoday #KidneyCancer #RCC #Belzutifan #AdjuvantTherapy #HIF2alpha #Immunotherapy #PrecisionOncology #GU26

Congratulations to Haitao Xu @PayalKapur5 @KCPUTSW and all consortium investigators @montypal @neerajaiims on insight.jci.org/articles/view/…

Feasibility of using an RNA-Seq biomarker to assign therapy in the #OPTIC RCC trial. @PBarataMD @caseccc joins @zklaassen_md @GACancerCenter highlighting the OPTIC RCC trial as a proof of concept for genomically guided therapy in metastatic clear cell kidney cancer, using RNA-sequencing to steer patients with angiogenic signatures to cabozantinib–nivolumab and those with inflammatory signatures to ipilimumab–nivolumab. #WatchNow > bit.ly/4tqJMlD

Adjuvant kidney cancer is evolving. @DrChoueiri joins the Uromigos to discuss the LITESPARK-022 phase 3 trial of belzutifan + pembrolizumab, mechanistic insights, biomarker development, and what may lie ahead for RCC research. Listen now! 🔗 GuOncology Now: buff.ly/nHHOJXH 🎧 Apple Podcasts: buff.ly/Fnzb9dJ 🎧 Spotify: buff.ly/uO54Gqr #Uromigos #GUOncology